About this Research Topic
COVID-19 was discovered in December 2019, and new therapeutics and novel approaches are still needed to treat it. Worldwide, researchers engaged in developing therapeutics are exploring COVID-19 prevention strategies, and therapeutic options including convalescent plasma, monoclonal antibodies, vaccines, peptides, interferons, small molecule drugs, and reutilizing proven drugs. While vaccination provides strong immune protection against COVID-19, however, developing effective vaccines is a long and challenging process. In addition, as new variants of COVID-19 emerge, vaccines too need to be modified accordingly and administered periodically to develop re-immune protection against new variants. Alternatively, antibody-based therapy can provide immediate effect for COVID-19 patients. Neutralizing antibodies (NAbs) target viral surface proteins by blocking the attachment of virus to the host cell. Several structural studies on SARS-CoV-2-antibody interaction clearly suggest neutralizing antibodies primarily target S(spike) protein, which mediates entry into the cells. Several scientific advancements have been achieved toward COVID-19 cure in recent times, and different strategies are under testing. One of the research lines drawing more attention is the development of approaches to block the virus-cell interaction. In fact, the combination of different approaches will be necessary to achieve the final aim of COVID-19 elimination.
We seek Original Research Articles, Reviews, Mini-Reviews, Perspectives, and Brief Research Reports that discuss the latest developments in immune-antibody technologies and protection strategies aimed at the recognition and clearance of COVID-19. More specifically, topics of interest include, but are not limited to:
- Monoclonal, either broadly neutralizing or non-neutralizing, and bispecific antibodies to
target COVID-19 spike protein-cell interaction.
- Hybridoma technology for developing effective neutralizing COVID-19 antibodies either for
treatment or detection.
- Clinical studies using neutralizing antibodies therapies as COVID-19 treatment
- Convalescent plasma technology.
- Genetic engineered COVID-19 antibodies for treatment or detection.
- Animal models to test immune and antibody-based approaches to eradicate COVID-19
infection in vivo.
- Small molecule COVID-19 inhibitors.
- Therapeutic vaccines.
We seek Original Research Articles, Reviews, Mini-Reviews, Perspectives, and Brief Research Reports that discuss the latest developments in immune-antibody technologies and protection strategies aimed at the recognition and clearance of COVID-19. More specifically, topics of interest include, but are not limited to:
- Monoclonal, either broadly neutralizing or non-neutralizing, and bispecific antibodies to
target COVID-19 spike protein-cell interaction.
- Hybridoma technology for developing effective neutralizing COVID-19 antibodies either for
treatment or detection.
- Clinical studies using neutralizing antibodies therapies as COVID-19 treatment
- Convalescent plasma technology.
- Genetic engineered COVID-19 antibodies for treatment or detection.
- Animal models to test immune and antibody-based approaches to eradicate COVID-19
infection in vivo.
- Small molecule COVID-19 inhibitors.
- Therapeutic vaccines.
Keywords: COVID-19, Antibody therapy, COVID-19 Elimination, COVID-19 Cure, Antibodies, Therapies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
